Pharming Group N.V. announces the nomination of Barbara Yanni and Mark Pykett to its Board of Supervisory Directors. An Extraordinary General Meeting of Shareholders is expected to be convened later this year for their official appointment. Until that moment, Barbara Yanni and Mark Pykett will hold an observational role within Pharming'sBoard of Supervisory Directors. Barbara Yanni has over thirty-five years of experience in pharmaceuticals and biotechnology. She currently serves as an independent director of three public clinical-stage biopharmaceutical companies, including Trevena, Vaccinex and Akcea. Mark Pykett is Chief Scientific Officer of PTC Therapeutics. Before joining PTC in 2018, Mark held a number of executive positions, including president and Chief Executive Officer (CEO) of Agilis Biotherapeutics, CEO of Navidea Biopharmaceuticals, and president and CEO of Alseres Pharmaceuticals.